|
Dr. Rossignol, a Sorbonne graduate, was trained as a synthetic medicinal chemist and physician, leading to an accomplished career as a research scientist. He spent 20 years in academia in France and in the United States before joining the pharmaceutical industry with Squibb Corporation in Princeton, New Jersey, in 1987. In 1993, Dr. Rossignol co-founded Romark Laboratories to develop one of his early inventions, nitazoxanide, the first of a new class of drugs called the thiazolides.
During his academic career, Dr. Rossignol developed albendazole, the first broad spectrum, single dose anthelminthic, and the antimalarial, halofantrine, both for SmithKline Beckman Corporation, today GlaxoSmithKline PLC. Both drugs received regulatory approvals in many countries, including the United States, and albendazole made the World Health Organization's Essential Drug List.
Dr. Rossignol has held numerous full-time and adjunct faculty positions, published more than 100 articles in scientific or medical journals and been awarded 25 US patents. For 11 years, he served first as a consultant and later as an expert in parasitic diseases for the World Health Organization in Geneva, Switzerland. He is currently affiliated with Stanford University School of Medicine. | 